Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2014-12-12 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 12, 2014, announcing the presentation of Phase 3 clinical trial results (SOFT study) regarding breast cancer treatment by Ipsen. It details efficacy data, quotes key personnel, describes the study methodology, and provides company/product background. This format—a formal announcement of significant clinical/business news, often released ahead of or alongside a formal regulatory filing—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of results and not a full periodic financial report (like 10-K or IR), and it is not explicitly a transcript (CT) or a presentation (IP), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content focuses heavily on clinical trial results and product updates rather than comprehensive quarterly financial performance highlights, and it is a formal press release format, it aligns closely with the function of an Earnings Release (ER) which often includes operational highlights, or RNS as a general announcement. However, since it is a specific announcement of study results presented at a symposium, and not a standard quarterly earnings summary, RNS (Regulatory Filings/General Announcement) is a safer classification if ER is reserved strictly for quarterly financial summaries. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement of clinical results. Therefore, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-standard operational announcement.
2014-12-12 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of November 30, 2014. This specific type of regular disclosure regarding share capital and voting rights does not perfectly align with the provided definitions (like 10-K, ER, or DIV). However, it is a mandatory regulatory disclosure concerning share structure. Since it is a specific, recurring regulatory update that doesn't fit the other specialized categories (like DIRS for director trades or SHA for capital changes), the most appropriate general regulatory filing category is 'Regulatory Filings' (RNS). The document length is very short (746 chars), but it is the report itself, not an announcement of a report.
2014-12-09 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2014). This content directly relates to the structure of the share capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital structure, or potentially a general regulatory filing (RNS). Given the specific focus on the total number of shares and voting rights, SHA is the most precise fit, as it covers capital structure changes/updates.
2014-12-09 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 28, 2014, announcing that the FDA accepted the supplemental Biologics License Application (sBLA) for Dysport® for treating upper limb spasticity in adults. It details the Phase III clinical study results and includes forward-looking statements and contact information for media/investors. This type of announcement, which communicates a significant regulatory event (FDA filing acceptance) and key clinical data outside of a formal periodic report (like 10-K or IR), is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific corporate/regulatory update that doesn't fit other categories perfectly (like M&A or Capital Change), it functions as a primary news announcement. Given the options, it is a specific corporate announcement about regulatory progress, which often accompanies or precedes earnings discussions, but is not the earnings release itself (ER) or a full report (IR/10-K). However, in the context of financial filings, press releases announcing key operational/regulatory milestones are often grouped with Earnings Releases (ER) as they provide material, time-sensitive information to investors. Since it is not a transcript (CT), a formal report (IR/10-K), or a proxy statement (DEF 14A), and it is a direct announcement of a material event, ER is the closest fit for a major, time-sensitive corporate update, although RNS (Regulatory Filings) is a strong fallback. Given the content is a major regulatory milestone announcement, ER is often used for such material news releases.
2014-11-28 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 28, 2014, announcing that the FDA has accepted the supplemental Biologics License Application (sBLA) for Dysport® for a new indication (upper limb spasticity). This is a specific corporate update regarding regulatory progress and clinical trial data, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It details a regulatory submission and its acceptance for review. This type of announcement, which is a specific corporate action/update that doesn't fit the other specialized categories (like M&A, Capital Change, Dividend), is best classified as a general Regulatory Filing or announcement. Given the options, 'Regulatory Filings (RNS)' serves as the best general category for specific, non-standard regulatory news releases that are not the full report itself. It is not a management change (MANG), director dealing (DIRS), or a formal legal proceeding report (LTR), but rather a positive regulatory milestone announcement.
2014-11-28 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 91% confidence The document is a press release dated November 20, 2014, announcing the creation of a joint research and innovation lab ("Archi-Pex") between Ipsen and CNRS, in collaboration with other entities. It details the purpose, duration, and key personnel involved. This type of announcement, which details strategic operational developments, partnerships, and scientific progress, does not fit neatly into the defined financial reporting categories (like 10-K, ER, IR, or DIV). It is a general corporate announcement regarding strategy and operations. Since it is not a formal regulatory filing like a 10-K or a specific financial event announcement, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that don't fit elsewhere, although it is closer to a strategic update than a typical RNS filing. Given the options, RNS is the best fit for a non-standard press release about a strategic partnership.
2014-11-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.